Dogwood Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Dogwood Therapeutics R&D Spending Growth & History (DWTX)
Dogwood Therapeutics's r&d spending was $21.9M for fiscal 2025.
View full Dogwood Therapeutics company overviewDogwood Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $21.9M | $18.3M | +519.28% |
| 2024 | 2024-12-31 | $3.5M | $1.8M | +104.33% |
| 2023 | 2023-12-31 | $1.7M | −$6.3M | −78.59% |
| 2022 | 2022-12-31 | $8.1M | −$2.7M | −25.25% |
| 2021 | 2021-12-31 | $10.8M | $10.6M | +5464.41% |
| 2020 | 2020-12-31 | $194,013 | — | — |
Dogwood Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.2M | $676,576 | +26.33% |
| Q1 2026 | 2026-03-31 | $2.7M | $232,781 | +9.55% |
| Q4 2025 | 2025-12-31 | $2.3M | $21,838 | +0.94% |
| Q3 2025 | 2025-09-30 | $14.5M | $14.0M | +2613.45% |
| Q2 2025 | 2025-06-30 | $2.6M | $2.2M | +664.67% |
| Q1 2025 | 2025-03-31 | $2.4M | $2.1M | +609.01% |
| Q4 2024 | 2024-12-31 | $2.3M | $2.0M | +676.33% |
| Q3 2024 | 2024-09-30 | $535,162 | $160,962 | +43.01% |
| Q2 2024 | 2024-06-30 | $336,084 | −$221,759 | −39.75% |
| Q1 2024 | 2024-03-31 | $343,717 | −$153,997 | −30.94% |
| Q4 2023 | 2023-12-31 | $298,321 | −$973,393 | −76.54% |
| Q3 2023 | 2023-09-30 | $374,200 | −$1.2M | −76.94% |
| Q2 2023 | 2023-06-30 | $557,843 | −$1.8M | −76.82% |
| Q1 2023 | 2023-03-31 | $497,714 | −$2.3M | −82.03% |
| Q4 2022 | 2022-12-31 | $1.3M | −$1.6M | −56.42% |
| Q3 2022 | 2022-09-30 | $1.6M | −$1.3M | −45.21% |
| Q2 2022 | 2022-06-30 | $2.4M | −$802,763 | −25.01% |
| Q1 2022 | 2022-03-31 | $2.8M | $1.1M | +62.22% |
| Q4 2021 | 2021-12-31 | $2.9M | $2.9M | +9000.69% |
| Q3 2021 | 2021-09-30 | $3.0M | $2.9M | +2639.60% |
| Q2 2021 | 2021-06-30 | $3.2M | $3.2M | +13661.58% |
| Q1 2021 | 2021-03-31 | $1.7M | $1.7M | +5489.43% |
| Q4 2020 | 2020-12-31 | $32,068 | — | — |
| Q3 2020 | 2020-09-30 | $108,086 | — | — |
| Q2 2020 | 2020-06-30 | $23,320 | — | — |
| Q1 2020 | 2020-03-31 | $30,539 | — | — |
Dogwood Therapeutics r&d spending trends
Over the last five fiscal years, Dogwood Therapeutics's r&d spending increased from $194,013 to $21.9M, a change of $21.7M. The latest reported quarter, Q2 2026, shows $3.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dogwood Therapeutics source filings ↗